News & Updates

In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.

Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.

For older acute coronary syndrome (ACS) patients with implanted bioabsorbable polymer sirolimus-eluting stents, a strategy involving ticagrelor monotherapy after 3‐month dual antiplatelet therapy (DAPT) is better than ticagrelor‐based 12‐month DAPT, according to a post hoc analysis of the TICO* trial. Furthermore, the beneficial effect of ticagrelor monotherapy increases with age and is strongest among patients aged ≥64 years.

Treatment with apremilast appears safe and effective against mild to moderate plaque psoriasis, according to a recent study.

The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.